Daily oral artesunate for people with pulmonary arterial hypertension — safety and tolerability

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center, open-label Phase 1 dose-escalation trial testing daily oral artesunate in adults with pulmonary arterial hypertension over 20 weeks. Participants are adults aged 18 to 75 with WHO functional class I–III disease despite maximally tolerated background therapy. The study will escalate doses to characterize safety, tolerability, and adverse event profiles while monitoring clinical status and laboratory parameters. Results will inform dosing and feasibility for future efficacy studies.

Why it matters

Who can join: the full rules

Inclusion Criteria

* Each participant must meet the following criteria to be enrolled in this study:
* Adults aged 18 to 75 years.
* WHO functional class I, II/III despite treatment with maximally tolerated doses of 2 or more treatment modalities including PDE5 inhibitors, guanylate cyclase stimulators, endothelin receptor antagonists, and prostanoids when appropriate.

Exclusion Criteria

* Participants who meet any of the following criteria will be excluded from the study.
* Participants with serious concomitant morbidity per investigator assessment.

Where it's running

• Stanford University
  Stanford, California, United States Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Sleep problems in PAH patients: how sleep breathing relates to PAH outcomes

  This study tests how sleep-disordered breathing and nocturnal oxygen changes relate to outcomes in adults with pulmonary arterial hypertension.

  Recruiting Chinese Pulmonary Vascular Disease Research Group · Beijing · NCT07852403

• Impact of ambient air vs nasal liquid oxygen on exercise performance in pulmonary vascular disease

  This study tests whether using nasal liquid oxygen during a 6-minute walk test changes how far patients with PAH or CTEPH can walk compared to breathing room air.

  Recruiting University of Zurich · Zurich, Canton of Zurich · NCT07777445

• Liquid oxygen vs ambient air during a 6-minute walk in people with pulmonary vascular disease

  This study tests whether walking with liquid oxygen at about 4 L/min helps or hinders distance walked compared with walking on room air in adults with PAH or CTEPH living in Switzerland.

  Recruiting University of Zurich · Zurich, Canton of Zurich · NCT07777367

• Treprostinil inhalation powder for PAH patients switching from selexipag

  This study tests whether inhaled treprostinil (LIQ861) is safe and tolerable for adults with PAH who are moving from oral selexipag to inhaled therapy.

  Recruiting Phase 4 Liquidia Technologies, Inc. · Columbus, Georgia · NCT07759804

• Escalation options for PAH patients already on dual therapy

  This trial tests whether adding a prostacyclin pathway drug or increasing sildenafil dose helps PAH patients at intermediate-to-high risk who aren’t at low risk despite dual therapy.

  Recruiting Phase 4 University of Sao Paulo General Hospital · São Paulo, São Paulo · NCT07713914

• Vasoactive Agents in Pulmonary Hypertension Crisis

  This trial tests whether dopamine, norepinephrine, or epinephrine can safely and effectively help people with a pulmonary hypertension crisis who are in the hospital.

  Recruiting China National Center for Cardiovascular Diseases · Beijing, Beijing Municipality and 2 other locations · NCT07667829

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.